Trials / Completed
CompletedNCT01787279
An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B
Expanded Access Programme of PEGASYS® (Peg Interferon Alpha-2a 40KD) in Patients With HBe-Ag-negative Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an expanded access programme to make Pegasys (peginterferon alfa-2a) available to patients with HBeAg-negative chronic hepatitis B in Morocco. Patients will receive Pegasys 180 mcg subcutaneously weekly for 48 weeks and efficacy and safety will be recorded during treatment and for 24 weeks of follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2a [Pegasys] | 180 mcg subcutaneously weekly, 48 weeks |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2013-02-08
- Last updated
- 2016-07-22
- Results posted
- 2016-07-22
Locations
4 sites across 1 country: Morocco
Source: ClinicalTrials.gov record NCT01787279. Inclusion in this directory is not an endorsement.